Abstract
Pyoderma gangrenosum (PG) is a rare, noninfectious, autoimmune neutrophilic dermatosis comprising significant diagnostic and therapeutic challenges. It often presents as painful ulcerations and is frequently associated with systemic diseases such as inflammatory bowel disease and rheumatoid arthritis. Standard treatments, including corticosteroids, methotrexate, cyclosporine, and biologics like infliximab, can have variable efficacy, necessitating individualized approaches. This case report describes a 21-year-old Iranian male with extensive ulcerative plaques unresponsive to conventional treatments. The patient's history of severe anemia and familial incidence of PG suggested an underlying genetic predisposition. Remarkably, the patient showed significant improvement with granulocyte colony-stimulating factor (GCSF) therapy, which is not a standard treatment for PG. The successful use of GCSF in this case highlights its potential as an additive or alternative therapy for refractory PG, likely due to its ability to enhance neutrophil function, modulate immune responses, and promote wound healing. This case emphasizes the importance of personalized treatment strategies and the need for further research into novel therapeutic options for PG.